In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...
Read MoreOngoing treatment(s)-Biological/Targeted therapy Posts on Medivizor
Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma
In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...
Read MoreEvaluating the effectiveness of stem cell transplant in patients with follicular lymphoma with early treatment failure
In a nutshell This study investigated the effectiveness of autologous stem cell transplantation (autoSCT) for patients with follicular lymphoma who experienced early treatment failure (ETF; relapse or disease progression within 2 years after first-line therapy). This study concluded that autoSCT may be an effective option for these patients. Some...
Read MoreEvaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read MoreEvaluating the impact of rituximab treatment on follicular lymphoma transformation
In a nutshell This study evaluated the impact of rituximab (Rituxan) treatment on the risk of lymphoma transformation (development of aggressive lymphoma) in patients with follicular lymphoma (FL). They concluded that this risk can be significantly reduced by the use of first-line (primary treatment) rituximab. Some background FL is the second most...
Read MoreMaintenance therapies for non-Hodgkin’s lymphomas
In a nutshell This article reviewed the outcomes and side effects associated with maintenance therapies for diffuse large B-cell lymphoma and mantle cell lymphoma. Some background After initial treatment, patients with diffuse large B-cell lymphoma (DLBCL) may have disease progression within 1 to 2 years. Patients with mantle cell lymphoma (MCL) may...
Read MoreCAR T-cell therapy for non-Hodgkin’s lymphoma
In a nutshell This article reviewed the effectiveness and safety of CAR T-cell therapy in patients with non-Hodgkin’s lymphoma. Some background The standard treatment for non-Hodgkin’s lymphoma (NHL) is chemotherapy plus immunotherapy. Patients with high-risk disease tend to become refractory (do not respond to treatment). For these...
Read MoreRespiratory side effects after R-CHOP for non-Hodgkin’s lymphoma
In a nutshell This study investigated respiratory side effects in patients with non-Hodgkin’s lymphoma (NHL) who received chemotherapy containing rituximab (Rituxan). This study concluded that these side effects are common and associated with increased mortality in these patients. Some background Non-Hodgkin’s lymphoma patients treated...
Read MoreChemotherapy after radiotherapy for early-stage follicular lymphoma
In a nutshell This study investigated the safety and effectiveness of systemic chemotherapy after radiotherapy for early-stage follicular lymphoma. This study concluded that this combined treatment is more effective than radiotherapy alone for early-stage follicular lymphoma. Some background Radiotherapy can help control local disease in more than 90%...
Read MoreLong-term outcomes of ibrutinib plus rituximab for relapsed or refractory mantle cell lymphoma
In a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...
Read MoreDoes ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read MoreLenalidomide and blood clots: low risk in CLL and NHL
In a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...
Read More